Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP069
MIFTS: 58

Hyperparathyroidism

Categories: Endocrine diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hyperparathyroidism

About this section

MalaCards integrated aliases for Hyperparathyroidism:

Name: Hyperparathyroidism 12 76 29 55 6 44 15 73

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:13543
ICD10 33 E21.3
ICD9CM 35 252.0 252.00
MeSH 44 D006961
NCIt 50 C48259
UMLS 73 C0020502
Sources

Summaries for Hyperparathyroidism

About this section
Disease Ontology : 12 A parathyroid gland disease characterized by an overactivity of the parathyroid glands, leading to an excess of parathyroid hormone in the body.

MalaCards based summary : Hyperparathyroidism is related to hyperparathyroidism 1 and hyperparathyroidism 2 with jaw tumors. An important gene associated with Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs Sevelamer and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and thyroid, and related phenotypes are cellular and cardiovascular system

Wikipedia : 76 Hyperparathyroidism is an increased parathyroid hormone (PTH) levels in the blood. This occurs either... more...

Sources

Related Diseases for Hyperparathyroidism

About this section

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism

Diseases related to Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 1 35.0 CDC73 MEN1
2 hyperparathyroidism 2 with jaw tumors 34.8 CASR CDC73 MEN1 RET
3 hyperparathyroidism 3 34.6 CDC73 GCM2 HRPT3 MEN1
4 hyperparathyroidism, neonatal severe 34.5 CASR PRKAR1A
5 osteitis fibrosa 33.3 BGLAP CALCA CASR PTH
6 pseudohypoparathyroidism, type ib 32.4 BGLAP PTH PTHLH
7 multiple endocrine neoplasia, type iia 32.4 CALCA CDC73 MEN1 PTH RET
8 parathyroid carcinoma 32.1 CALCA CASR CDC73 MEN1 PTH RET
9 vitamin d-dependent rickets, type 2a 31.8 CYP27B1 VDR
10 familial hypocalciuric hypercalcemia 31.5 CASR CDC73 PTH
11 adenoma 31.5 CASR CDC73 MEN1 RET
12 multiple endocrine neoplasia, type i 30.8 CASR CDC73 CDKN1B CHGA MEN1 PRKAR1A
13 parathyroid transitional clear cell adenoma 30.6 MEN1 PTH
14 pseudohypoparathyroidism 30.6 BGLAP PTH PTHLH
15 rickets 30.5 BGLAP CYP27B1 FGF23 PHEX PTH VDR
16 clear cell adenoma 30.5 MEN1 PTH PTHLH
17 chief cell adenoma 30.5 GCM2 PTH
18 fibrous dysplasia 30.3 BGLAP CALCA FGF23
19 calciphylaxis 30.3 CASR EPO FGF23 PTH VDR
20 giant cell tumor 30.3 BGLAP CALCA TNFRSF11B
21 pheochromocytoma 30.2 CALCA CHGA MEN1 RET
22 follicular adenoma 30.1 CALCA CDKN1B RET
23 invasive malignant thymoma 30.1 PTH PTHLH
24 uremia 30.0 CASR EPO PTH TNFRSF11B VDR
25 calcinosis 29.9 CALCA FGF23 PHEX
26 carcinoid syndrome 29.9 CALCA CHGA MEN1
27 differentiated thyroid carcinoma 29.8 BGLAP RET TNFRSF11B
28 kidney disease 29.8 CASR EPO FGF23 PTH TNFRSF11B VDR
29 multiple endocrine neoplasia 29.7 CALCA CDKN1B CHGA MEN1 PRKAR1A RET
30 hypophosphatemia 29.7 BGLAP FGF23 PHEX PTH
31 parathyroid gland disease 29.7 BGLAP CALCA CASR CDC73 FGF23 GCM2
32 acute thyroiditis 29.7 CALCA CHGA
33 primary hyperparathyroidism 29.7 BGLAP CALCA CASR CDC73 CDKN1B CHGA
34 parathyroid adenoma 29.6 BGLAP CALCA CASR CDC73 CHGA GCM2
35 hypoparathyroidism 29.6 BGLAP CASR FGF23 GCM2 PTH PTHLH
36 secondary hyperparathyroidism of renal origin 29.6 ACP5 BGLAP CALCA CASR CYP27B1 EPO
37 thyroid carcinoma, familial medullary 29.5 CALCA CHGA MEN1 RET
38 oncogenic osteomalacia 29.5 FGF23 PHEX PTH PTHLH
39 hyperphosphatemia 29.4 CASR FGF23 GCM2 PHEX PTH VDR
40 renal osteodystrophy 29.4 BGLAP CALCA CASR FGF23 PTH TNFRSF11B
41 hypophosphatemic rickets, x-linked recessive 29.4 CYP27B1 FGF23 PHEX VDR
42 hypervitaminosis d 29.3 CYP27B1 FGF23 PTH VDR
43 islet cell tumor 29.3 CALCA CHGA MEN1 PTHLH
44 hypocalcemia, autosomal dominant 1 29.3 CALCA CASR GCM2 PRKAR1A VDR
45 osteomalacia 28.8 BGLAP CALCA CASR FGF23 PHEX PTHLH
46 hypophosphatemic rickets, x-linked dominant 28.6 CYP27B1 FGF23 PHEX PTH VDR
47 paget's disease of bone 28.6 ACP5 BGLAP CALCA PTH TNFRSF11B
48 chronic kidney failure 28.0 BGLAP CALCA CASR CYP27B1 EPO FGF23
49 bone disease 27.1 ACP5 BGLAP CALCA CASR FGF23 PTH
50 osteoporosis 25.4 ACP5 BGLAP CALCA CASR CYP27B1 FGF23

Comorbidity relations with Hyperparathyroidism via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Hypertension, Essential
Hypoparathyroidism Hypothyroidism
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Parathyroid Carcinoma

Graphical network of the top 20 diseases related to Hyperparathyroidism:



Diseases related to Hyperparathyroidism
Sources

Symptoms & Phenotypes for Hyperparathyroidism

About this section

MGI Mouse Phenotypes related to Hyperparathyroidism:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 CYP27B1 GCM2 EPO MEN1 PHEX PTH
2 cardiovascular system MP:0005385 10.38 CYP27B1 EPO MEN1 FGF23 PTH PTHLH
3 growth/size/body region MP:0005378 10.36 FGF23 CYP27B1 MEN1 PTH PHEX PRKAR1A
4 homeostasis/metabolism MP:0005376 10.35 FGF23 CYP27B1 GCM2 EPO MEN1 PTH
5 endocrine/exocrine gland MP:0005379 10.34 CYP27B1 GCM2 MEN1 FGF23 PTH PTHLH
6 hematopoietic system MP:0005397 10.31 FGF23 CYP27B1 EPO PTH PHEX PRKAR1A
7 immune system MP:0005387 10.3 CYP27B1 EPO MEN1 FGF23 PHEX PTH
8 craniofacial MP:0005382 10.29 GCM2 MEN1 PHEX PTHLH PRKAR1A PTH
9 digestive/alimentary MP:0005381 10.24 FGF23 MEN1 PHEX PTHLH PRKAR1A RET
10 mortality/aging MP:0010768 10.24 FGF23 GCM2 EPO MEN1 PTH PHEX
11 integument MP:0010771 10.09 FGF23 CYP27B1 EPO PTHLH PRKAR1A VDR
12 limbs/digits/tail MP:0005371 10.06 FGF23 CYP27B1 EPO PTH PHEX PTHLH
13 adipose tissue MP:0005375 10.05 CYP27B1 PHEX PTHLH PRKAR1A CDC73 CDKN1B
14 renal/urinary system MP:0005367 10 GCM2 FGF23 PTHLH RET PHEX VDR
15 muscle MP:0005369 9.97 CYP27B1 EPO MEN1 PRKAR1A VDR RET
16 reproductive system MP:0005389 9.85 FGF23 CYP27B1 MEN1 PTHLH PRKAR1A VDR
17 respiratory system MP:0005388 9.5 FGF23 EPO PTHLH PRKAR1A RET CDKN1B
18 skeleton MP:0005390 9.44 GCM2 EPO FGF23 PHEX PTHLH PRKAR1A
Sources

Drugs & Therapeutics for Hyperparathyroidism

About this section

Drugs for Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
6
Calcium acetate Approved, Investigational Phase 4,Phase 3,Not Applicable 62-54-4
7
Racepinephrine Approved Phase 4 329-65-7 838
8
Denosumab Approved Phase 4,Phase 3,Phase 1 615258-40-7
9
Zoledronic acid Approved Phase 4,Phase 1 118072-93-8 68740
10
Alendronate Approved Phase 4,Phase 2,Not Applicable 121268-17-5, 66376-36-1 2088
11
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
12
Pamidronate Approved Phase 4 40391-99-9 4674
13
Ethanol Approved Phase 4 64-17-5 702
14
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
15
Iron Approved Phase 4 7439-89-6 23925
16
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 32222-06-3 134070 5280453
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1406-16-2
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
19 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
20
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 67-97-0 6221 5280795
21
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-14-6 5280793
22
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 41294-56-8 5282181
23
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
25
Phytonadione Approved, Investigational, Nutraceutical Phase 4 84-80-0 4812 5284607
26
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
27
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
28 Calcifediol Phase 4,Phase 3,Phase 1,Not Applicable 19356-17-3
29 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Retinol palmitate Phase 4
31 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2
38 Angiotensin Receptor Antagonists Phase 4,Phase 2
39 Angiotensinogen Phase 4,Phase 2
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2,Not Applicable
43 Epinephryl borate Phase 4
44 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Hypolipidemic Agents Phase 4,Phase 2,Not Applicable
46 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
49 Lipid Regulating Agents Phase 4,Phase 2,Not Applicable
50 Antimetabolites Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 336)
# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
3 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Unknown status NCT02572960 Phase 4 Valsartan;Placebo Valsartan
4 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
5 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
6 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
7 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
8 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
9 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
10 Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
11 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
12 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
13 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
14 Evaluation of a Cincalcet Suppression Test Completed NCT01103206 Phase 4 cinacalcet;cinacalcet dose 1;cinacalcet dose 2
15 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer Completed NCT00037518 Phase 4 AMG 073
16 Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
17 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
18 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
19 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
20 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
21 Vitamin D Repletion in Primary Hyperparathyroidism Completed NCT01306656 Phase 4 10,000 IU Vitamin D3
22 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
23 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
24 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
25 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
26 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
27 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
28 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
29 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
30 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
31 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
32 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
33 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
34 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
35 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
36 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
37 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
38 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
39 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
40 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
41 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
42 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
43 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
44 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
45 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
46 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
47 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
48 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
49 Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation Completed NCT02249741 Phase 4 Treated with Ibandronic acid as per protocol
50 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4

Search NIH Clinical Center for Hyperparathyroidism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperparathyroidism

Sources

Genetic Tests for Hyperparathyroidism

About this section

Genetic tests related to Hyperparathyroidism:

# Genetic test Affiliating Genes
1 Hyperparathyroidism 29
Sources

Anatomical Context for Hyperparathyroidism

About this section

MalaCards organs/tissues related to Hyperparathyroidism:

41
Kidney, Bone, Thyroid, Testes, Endothelial, Liver, Heart
Sources

Publications for Hyperparathyroidism

About this section

Articles related to Hyperparathyroidism:

(show top 50) (show all 2156)
# Title Authors Year
1
Calcitriol accelerates vascular calcification irrespective of vitamin K status in a rat model of CKD with hyperphosphatemia and secondary hyperparathyroidism. ( 29903718 )
2018
2
Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. ( 29108698 )
2018
3
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
4
Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism. ( 29879701 )
2018
5
Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy. ( 29929906 )
2018
6
Calciphylaxis as cutaneous marker of hyperparathyroidism and successful outcome with parathyroidectomy followed by hyperbaric oxygen therapy. ( 29451194 )
2018
7
Predictors of Readmission and Reoperation in Patients Undergoing Parathyroidectomy for Primary Hyperparathyroidism. ( 29436275 )
2018
8
Uremic leontiasis ossea, a rare presentation of severe renal osteodystrophy secondary to hyperparathyroidism. ( 29037869 )
2018
9
Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. ( 29423207 )
2018
10
Selective parathyroid venous sampling in primary hyperparathyroidism: A systematic review and meta-analysis. ( 29756350 )
2018
11
An unusual etiology of hyperparathyroidism: robotic-assisted resection of a giant functional intrathymic parathyroid cyst. ( 29963377 )
2018
12
Influence of Parathyroidectomy on Bone Metabolism and Bone Pain in Patients with Secondary Hyperparathyroidism. ( 29393259 )
2018
13
Re: Surgery for Primary Hyperparathyroidism: Adherence to Consensus Guidelines in an Academic Health System. ( 29357552 )
2018
14
REDUCTION OF ARRHYTHMIAS IN PRIMARY HYPERPARATHYROIDISM, BY PARATHYROIDECTOMY, EVALUATED WITH 24 HOUR ECG MONITORING. ( 29875287 )
2018
15
Normocalcaemic primary hyperparathyroidism: a pragmatic approach. ( 29437827 )
2018
16
Long-Term Skeletal Outcomes of Primary Hyperparathyroidism Patients After Treatment with Parathyroidectomy: A Systematic Review and Meta-Analysis. ( 29381879 )
2018
17
The relationship between semiquantitative parameters derived from technetium-99m metoxyisobutylisonitrile dual-phase parathyroid single-photon emission computed tomography images and disease severity in primary hyperparathyroidism. ( 29360693 )
2018
18
Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. ( 29910605 )
2018
19
Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism. ( 29364518 )
2018
20
Dual energy computed tomography should be the first line preoperative localization imaging test for primary hyperparathyroidism patients. ( 29370881 )
2018
21
Predictors of renal function and calcifications in primary hyperparathyroidism: A nested case-control study. ( 29955845 )
2018
22
Current opinions on nephrolithiasis associated with primary hyperparathyroidism. ( 29350243 )
2018
23
<sup>18</sup>F-Fluorocholine-Positron Emission Tomography/Computerised Tomography is Useful in Localising <sup>99m</sup>Tc-Sesta-methoxyisobutylisonitrile-Negative Parathyroid Cyst Causing Normocalcemic Primary Hyperparathyroidism. ( 29922354 )
2018
24
Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ? ( 29392434 )
2018
25
Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. ( 29928157 )
2018
26
Familial isolated hyperparathyroidism due to HRPT2 mutation. ( 29941370 )
2018
27
Mito-micea88 and mitochondrial DNA mutator mice as models of human osteoporosis caused not by aging but by hyperparathyroidism. ( 29973435 )
2018
28
Trabecular Bone Score in Obese and Non-obese Subjects with Primary Hyperparathyroidism Before and After Parathyroidectomy. ( 29373705 )
2018
29
Inherited Deletion of 1q, Hyperparathyroidism, and Signs of Y-Chromosomal Influence in a Patient with Turner Syndrome. ( 29739732 )
2018
30
Clinical value of 11C-methionine positron emission tomography in persistent primary hyperparathyroidism-A case report with a mediastinal parathyroid adenoma. ( 29573598 )
2018
31
Preterm Parturient with Polyhydramnios and Pancreatitis: Primary Presentation of Hyperparathyroidism. ( 29607233 )
2018
32
Morbidity in parathyroid surgery for renal disease is under reported: a comparison of outcomes with primary hyperparathyroidism. ( 29962299 )
2018
33
Initial surgical results of 500 Parathyroidectomies for Hyperparathyroidism related to chronic kidney disease - mineral and bone disorder. ( 29944161 )
2018
34
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. ( 29439405 )
2018
35
The influence of thyroid diseases, diabetes mellitus, primary hyperparathyroidism, vitamin B12 deficiency and other comorbid autoimmune diseases on treatment outcome in patients with rheumatoid arthritis: An exploratory cohort study. ( 29794789 )
2018
36
Periosteal chondroma of the cuboid with secondary aneurysmal bone cyst in a setting of secondary hyperparathyroidism. ( 29413778 )
2018
37
Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. ( 29405278 )
2018
38
Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. ( 29492624 )
2018
39
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. ( 29440923 )
2018
40
Gitelman syndrome and primary hyperparathyroidism: a rare association. ( 29871958 )
2018
41
Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report. ( 29359203 )
2018
42
Familial Hypocalciuric Hypercalcemia as an Atypical Form of Primary Hyperparathyroidism. ( 29115694 )
2018
43
A rare cause of primary hyperparathyroidism: Parathyroid lipoadenoma. ( 29778311 )
2018
44
Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. ( 29907149 )
2018
45
Highly specific preoperative selection of solitary parathyroid adenoma cases in primary hyperparathyroidism by quantitative image analysis of the early-phase Technetium-99m sestamibi scan. ( 29877611 )
2018
46
Influence of concurrent chronic kidney disease on intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism. ( 29128188 )
2018
47
Prevalence and Risk of Vertebral Fractures in Primary Hyperparathyroidism: A Nested Case-Control Study. ( 29734476 )
2018
48
Osteolytic lesions (brown tumors) of primary hyperparathyroidism misdiagnosed as multifocal giant cell tumor of the distal ulna and radius: a case report. ( 29936913 )
2018
49
Preoperative localization modalities in primary hyperparathyroidism: Correlation with postoperative cure. ( 29699804 )
2018
50
Primary hyperparathyroidism diagnosed and treated surgically during pregnancy. ( 29429952 )
2018
Sources

Variations for Hyperparathyroidism

About this section

ClinVar genetic disease variations for Hyperparathyroidism:

6
(show top 50) (show all 60)
# Gene Variation Type Significance SNP ID Assembly Location
1 MEN1 NM_000244.3(MEN1): c.578C> T (p.Pro193Leu) single nucleotide variant Uncertain significance rs199706698 GRCh37 Chromosome 11, 64575454: 64575454
2 MEN1 NM_000244.3(MEN1): c.578C> T (p.Pro193Leu) single nucleotide variant Uncertain significance rs199706698 GRCh38 Chromosome 11, 64807982: 64807982
3 MEN1 NM_000244.3(MEN1): c.526C> T (p.Arg176Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs143329068 GRCh37 Chromosome 11, 64575506: 64575506
4 MEN1 NM_000244.3(MEN1): c.526C> T (p.Arg176Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs143329068 GRCh38 Chromosome 11, 64808034: 64808034
5 MEN1 NM_130799.2(MEN1): c.1535C> T (p.Ser512Leu) single nucleotide variant Uncertain significance rs141679530 GRCh38 Chromosome 11, 64804632: 64804632
6 MEN1 NM_130799.2(MEN1): c.1535C> T (p.Ser512Leu) single nucleotide variant Uncertain significance rs141679530 GRCh37 Chromosome 11, 64572104: 64572104
7 MEN1 NM_130799.2(MEN1): c.1764G> A (p.Lys588=) single nucleotide variant Conflicting interpretations of pathogenicity rs373669288 GRCh38 Chromosome 11, 64804403: 64804403
8 MEN1 NM_130799.2(MEN1): c.1764G> A (p.Lys588=) single nucleotide variant Conflicting interpretations of pathogenicity rs373669288 GRCh37 Chromosome 11, 64571875: 64571875
9 MEN1 NM_130799.2(MEN1): c.*557C> A single nucleotide variant Uncertain significance rs886048471 GRCh38 Chromosome 11, 64803777: 64803777
10 MEN1 NM_130799.2(MEN1): c.*557C> A single nucleotide variant Uncertain significance rs886048471 GRCh37 Chromosome 11, 64571249: 64571249
11 MEN1 NM_130799.2(MEN1): c.*529A> G single nucleotide variant Uncertain significance rs886048472 GRCh38 Chromosome 11, 64803805: 64803805
12 MEN1 NM_130799.2(MEN1): c.*529A> G single nucleotide variant Uncertain significance rs886048472 GRCh37 Chromosome 11, 64571277: 64571277
13 MEN1 NM_130799.2(MEN1): c.*527G> T single nucleotide variant Uncertain significance rs886048473 GRCh37 Chromosome 11, 64571279: 64571279
14 MEN1 NM_130799.2(MEN1): c.*527G> T single nucleotide variant Uncertain significance rs886048473 GRCh38 Chromosome 11, 64803807: 64803807
15 MEN1 NM_130799.2(MEN1): c.*392G> A single nucleotide variant Uncertain significance rs886048475 GRCh37 Chromosome 11, 64571414: 64571414
16 MEN1 NM_130799.2(MEN1): c.*392G> A single nucleotide variant Uncertain significance rs886048475 GRCh38 Chromosome 11, 64803942: 64803942
17 MEN1 NM_130799.2(MEN1): c.*302C> T single nucleotide variant Likely benign rs1804849 GRCh37 Chromosome 11, 64571504: 64571504
18 MEN1 NM_130799.2(MEN1): c.*302C> T single nucleotide variant Likely benign rs1804849 GRCh38 Chromosome 11, 64804032: 64804032
19 MEN1 NM_130799.2(MEN1): c.*272T> C single nucleotide variant Uncertain significance rs563783609 GRCh37 Chromosome 11, 64571534: 64571534
20 MEN1 NM_130799.2(MEN1): c.*272T> C single nucleotide variant Uncertain significance rs563783609 GRCh38 Chromosome 11, 64804062: 64804062
21 MEN1 NM_130799.2(MEN1): c.*185C> T single nucleotide variant Likely benign rs111895237 GRCh37 Chromosome 11, 64571621: 64571621
22 MEN1 NM_130799.2(MEN1): c.*185C> T single nucleotide variant Likely benign rs111895237 GRCh38 Chromosome 11, 64804149: 64804149
23 MEN1 NM_130799.2(MEN1): c.*89G> A single nucleotide variant Uncertain significance rs886048478 GRCh37 Chromosome 11, 64571717: 64571717
24 MEN1 NM_130799.2(MEN1): c.*89G> A single nucleotide variant Uncertain significance rs886048478 GRCh38 Chromosome 11, 64804245: 64804245
25 MEN1 NM_130799.2(MEN1): c.-23-14G> C single nucleotide variant Uncertain significance rs886048479 GRCh37 Chromosome 11, 64577618: 64577618
26 MEN1 NM_130799.2(MEN1): c.-23-14G> C single nucleotide variant Uncertain significance rs886048479 GRCh38 Chromosome 11, 64810146: 64810146
27 MEN1 NM_130799.2(MEN1): c.*560G> T single nucleotide variant Uncertain significance rs886048470 GRCh38 Chromosome 11, 64803774: 64803774
28 MEN1 NM_130799.2(MEN1): c.*560G> T single nucleotide variant Uncertain significance rs886048470 GRCh37 Chromosome 11, 64571246: 64571246
29 MEN1 NM_130799.2(MEN1): c.*470A> G single nucleotide variant Uncertain significance rs778272737 GRCh37 Chromosome 11, 64571336: 64571336
30 MEN1 NM_130799.2(MEN1): c.*470A> G single nucleotide variant Uncertain significance rs778272737 GRCh38 Chromosome 11, 64803864: 64803864
31 MEN1 NM_130799.2(MEN1): c.-35A> T single nucleotide variant Benign/Likely benign rs679946 GRCh37 Chromosome 11, 64578113: 64578113
32 MEN1 NM_130799.2(MEN1): c.-35A> T single nucleotide variant Benign/Likely benign rs679946 GRCh38 Chromosome 11, 64810641: 64810641
33 MEN1 NM_130799.2(MEN1): c.*794G> A single nucleotide variant Uncertain significance rs117705251 GRCh38 Chromosome 11, 64803540: 64803540
34 MEN1 NM_130799.2(MEN1): c.*794G> A single nucleotide variant Uncertain significance rs117705251 GRCh37 Chromosome 11, 64571012: 64571012
35 MEN1 NM_130799.2(MEN1): c.*570C> A single nucleotide variant Uncertain significance rs886048469 GRCh38 Chromosome 11, 64803764: 64803764
36 MEN1 NM_130799.2(MEN1): c.*570C> A single nucleotide variant Uncertain significance rs886048469 GRCh37 Chromosome 11, 64571236: 64571236
37 MEN1 NM_130799.2(MEN1): c.*533C> T single nucleotide variant Uncertain significance rs879327862 GRCh38 Chromosome 11, 64803801: 64803801
38 MEN1 NM_130799.2(MEN1): c.*533C> T single nucleotide variant Uncertain significance rs879327862 GRCh37 Chromosome 11, 64571273: 64571273
39 MEN1 NM_130799.2(MEN1): c.*307T> G single nucleotide variant Likely benign rs1804848 GRCh37 Chromosome 11, 64571499: 64571499
40 MEN1 NM_130799.2(MEN1): c.*307T> G single nucleotide variant Likely benign rs1804848 GRCh38 Chromosome 11, 64804027: 64804027
41 MEN1 NM_130799.2(MEN1): c.327A> C (p.Glu109Asp) single nucleotide variant Uncertain significance rs773976527 GRCh37 Chromosome 11, 64577255: 64577255
42 MEN1 NM_130799.2(MEN1): c.327A> C (p.Glu109Asp) single nucleotide variant Uncertain significance rs773976527 GRCh38 Chromosome 11, 64809783: 64809783
43 MEN1 NM_130799.2(MEN1): c.61C> A (p.Arg21Ser) single nucleotide variant Uncertain significance rs541476418 GRCh37 Chromosome 11, 64577521: 64577521
44 MEN1 NM_130799.2(MEN1): c.61C> A (p.Arg21Ser) single nucleotide variant Uncertain significance rs541476418 GRCh38 Chromosome 11, 64810049: 64810049
45 MEN1 NM_130799.2(MEN1): c.-106T> C single nucleotide variant Uncertain significance rs886048481 GRCh37 Chromosome 11, 64578184: 64578184
46 MEN1 NM_130799.2(MEN1): c.-106T> C single nucleotide variant Uncertain significance rs886048481 GRCh38 Chromosome 11, 64810712: 64810712
47 MEN1 NM_130799.2(MEN1): c.*438C> T single nucleotide variant Uncertain significance rs886048474 GRCh37 Chromosome 11, 64571368: 64571368
48 MEN1 NM_130799.2(MEN1): c.*438C> T single nucleotide variant Uncertain significance rs886048474 GRCh38 Chromosome 11, 64803896: 64803896
49 MEN1 NM_130799.2(MEN1): c.*373G> C single nucleotide variant Uncertain significance rs886048476 GRCh37 Chromosome 11, 64571433: 64571433
50 MEN1 NM_130799.2(MEN1): c.*373G> C single nucleotide variant Uncertain significance rs886048476 GRCh38 Chromosome 11, 64803961: 64803961
Sources

Expression for Hyperparathyroidism

About this section
Search GEO for disease gene expression data for Hyperparathyroidism.
Sources

Pathways for Hyperparathyroidism

About this section

Pathways related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Parathyroid hormone synthesis, secretion and action 37
11.25 BGLAP CASR CYP27B1 FGF23 GCM2 PTH
2
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.14 BGLAP PRKAR1A PTH PTHLH VDR
3
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.09 BGLAP CALCA CYP27B1 PTH TNFRSF11B VDR
4
Osteoblast Signaling 1
10.7 BGLAP FGF23 PTH TNFRSF11B
5
Osteoclast Signaling 1
10.57 ACP5 TNFRSF11B
6
Vitamin D Metabolism 1
10.5 CYP27B1 PTH VDR
Sources

GO Terms for Hyperparathyroidism

About this section

Cellular components related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 BGLAP CALCA CHGA EPO FGF23 PTH

Biological processes related to Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 BGLAP CDKN1B PTH RET TNFRSF11B
2 negative regulation of cell proliferation GO:0008285 9.97 CDC73 CDKN1B CYP27B1 MEN1 PTHLH VDR
3 response to lipopolysaccharide GO:0032496 9.89 ACP5 CYP27B1 EPO TNFRSF11B
4 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.79 CALCA PTH PTHLH
5 negative regulation of epithelial cell proliferation GO:0050680 9.77 CDC73 CDKN1B MEN1
6 cellular calcium ion homeostasis GO:0006874 9.72 CALCA CASR GCM2 PTH VDR
7 response to estrogen GO:0043627 9.71 BGLAP CYP27B1 EPO TNFRSF11B
8 decidualization GO:0046697 9.69 CYP27B1 MEN1 VDR
9 bone mineralization GO:0030282 9.67 BGLAP CYP27B1 PHEX PTHLH
10 negative regulation of chondrocyte differentiation GO:0032331 9.65 PTH PTHLH
11 positive regulation of ossification GO:0045778 9.65 CALCA PTH
12 obsolete positive regulation of cAMP biosynthetic process GO:0030819 9.65 PTH PTHLH
13 regulation of bone mineralization GO:0030500 9.65 BGLAP CYP27B1 FGF23
14 response to inorganic substance GO:0010035 9.64 BGLAP TNFRSF11B
15 positive regulation of keratinocyte differentiation GO:0045618 9.64 CYP27B1 VDR
16 negative regulation of bone resorption GO:0045779 9.63 CALCA TNFRSF11B
17 positive regulation of cAMP metabolic process GO:0030816 9.63 CALCA CHGA
18 osteoblast development GO:0002076 9.63 BGLAP MEN1 PTHLH
19 response to magnesium ion GO:0032026 9.62 FGF23 TNFRSF11B
20 cellular response to parathyroid hormone stimulus GO:0071374 9.61 FGF23 PHEX
21 cellular phosphate ion homeostasis GO:0030643 9.61 FGF23 GCM2
22 vitamin D metabolic process GO:0042359 9.61 CYP27B1 FGF23 VDR
23 response to fibroblast growth factor GO:0071774 9.58 CASR PTH
24 negative regulation of calcium ion transport into cytosol GO:0010523 9.58 CALCA EPO
25 cAMP metabolic process GO:0046058 9.56 PTH PTHLH
26 vitamin D catabolic process GO:0042369 9.55 CYP27B1 FGF23
27 response to sodium phosphate GO:1904383 9.54 FGF23 PHEX
28 response to vitamin D GO:0033280 9.46 BGLAP CYP27B1 PHEX PTH
29 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.43 CYP27B1 FGF23 VDR
30 skeletal system development GO:0001501 9.43 BGLAP PHEX PTH PTHLH TNFRSF11B VDR
31 cellular response to vitamin D GO:0071305 8.92 BGLAP CASR FGF23 PHEX
32 regulation of signaling receptor activity GO:0010469 10 CALCA EPO FGF23 PTH PTHLH TNFRSF11B

Molecular functions related to Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 8.96 PTH PTHLH
2 hormone activity GO:0005179 8.92 CALCA EPO PTH PTHLH
Sources

Sources for Hyperparathyroidism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....